Design, Synthesis and Evaluation of N-pyrazinylbenzamides as Potential Antimycobacterial Agents

Three series of N-(pyrazin-2-yl)benzamides were designed as retro-amide analogues of previously published N-phenylpyrazine-2-carboxamides with in vitro antimycobacterial activity. The synthesized retro-amides were evaluated for in vitro growth inhibiting activity against Mycobacterium tuberculosis H37Rv (Mtb), three non-tuberculous mycobacterial strains (M. avium, M. kansasii, M. smegmatis) and selected bacterial and fungal strains of clinical importance. Regarding activity against Mtb, most N-pyrazinylbenzamides (retro-amides) possessed lower or no activity compared to the corresponding N-phenylpyrazine-2-carboxamides with the same substitution pattern. However, the active retro-amides tended to have lower HepG2 cytotoxicity and better selectivity. Derivatives with 5-chloro substitution on the pyrazine ring were generally more active compared to their 6-cloro positional isomers or non-chlorinated analogues. The best antimycobacterial activity against Mtb was found in N-(5-chloropyrazin-2-yl)benzamides with short alkyl (2h: R2 = Me; 2i: R2 = Et) in position 4 of the benzene ring (MIC = 6.25 and 3.13 µg/mL, respectively, with SI > 10). N-(5-Chloropyrazin-2-yl)benzamides with hydroxy substitution (2b: R2 = 2-OH; 2d: R2 = 4-OH) on the benzene ring or their acetylated synthetic precursors possessed the broadest spectrum of activity, being active in all three groups of mycobacterial, bacterial and fungal strains. The substantial differences in in silico calculated properties (hydrogen-bond pattern analysis, molecular electrostatic potential, HOMO and LUMO) can justify the differences in biological activities between N-pyrazinylbenzamides and N-phenylpyrazine-2-carboxamides.

[1]  Jing Zhao,et al.  Design, synthesis, and SAR study of 3-(benzo[d][1,3]dioxol-5-yl)-N-benzylpropanamide as novel potent synergists against fluconazole-resistant Candida albicans. , 2017, Bioorganic & medicinal chemistry letters.

[2]  N. Dillon,et al.  Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA , 2017, Scientific Reports.

[3]  Peter J Dodd,et al.  The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling , 2016, PLoS medicine.

[4]  M. Doležal,et al.  Spectroscopic, quantum chemical studies, Fukui functions, in vitro antiviral activity and molecular docking of 5-chloro-N-(3-nitrophenyl)pyrazine-2-carboxamide , 2016 .

[5]  J. Kaur,et al.  Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis. , 2016, Gene.

[6]  L. Navrátilová,et al.  Design, synthesis and anti-mycobacterial evaluation of some new N-phenylpyrazine-2-carboxamides , 2015, Chemical Papers.

[7]  L. Naesens,et al.  Synthesis and Antimicrobial Evaluation of 6‐Alkylamino‐N‐phenylpyrazine‐2‐carboxamides , 2015, Chemical biology & drug design.

[8]  S. Bősze,et al.  Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates. , 2015, European journal of medicinal chemistry.

[9]  Mahavir Singh,et al.  Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria , 2015, Expert review of anti-infective therapy.

[10]  D. Lin,et al.  Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide , 2014, Molecular microbiology.

[11]  K. Shibayama,et al.  Biochemical Characterization of Quinolinic Acid Phosphoribosyltransferase from Mycobacterium tuberculosis H37Rv and Inhibition of Its Activity by Pyrazinamide , 2014, PloS one.

[12]  Peng Cui,et al.  Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis , 2014, Emerging Microbes & Infections.

[13]  M. Gogou,et al.  Insights into the N,N-diacylation reaction of 2-aminopyrimidines and deactivated anilines: an alternative N-monoacylation reaction , 2013 .

[14]  O. Soukup,et al.  Synthesis, Antimycobacterial Activity and In Vitro Cytotoxicity of 5-Chloro-N-phenylpyrazine-2-carboxamides , 2013, Molecules.

[15]  W. Shi,et al.  Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis , 2013, Emerging Microbes & Infections.

[16]  M. Lourenço,et al.  Synthesis and Antitubercular Evaluation of N-Arylpyrazine and N,N′-Alkyl-diylpyrazine-2-carboxamide Derivatives , 2012 .

[17]  M. Krátký,et al.  Salicylanilide ester prodrugs as potential antimicrobial agents--a review. , 2011, Current pharmaceutical design.

[18]  M. Doležal,et al.  Antimycobacterial evaluation of pyrazinoic acid reversible derivatives. , 2011, Current pharmaceutical design.

[19]  Ying Zhang,et al.  Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis , 2011, Science.

[20]  W. Jacobs,et al.  Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I. , 2011, Bioorganic & medicinal chemistry letters.

[21]  V. Buchta,et al.  Synthesis, Antimycobacterial, Antifungal and Photosynthesis-Inhibiting Activity of Chlorinated N-phenylpyrazine-2-carboxamides † , 2010, Molecules.

[22]  T. Hirano,et al.  Synthesis and fluorescence properties of difluoro[amidopyrazinato-O,N]boron derivatives: a new boron-containing fluorophore , 2010 .

[23]  R. Pratt,et al.  Substituted aryl malonamates as new serine beta-lactamase substrates: structure-activity studies. , 2010, Bioorganic & medicinal chemistry.

[24]  Lynn Rasmussen,et al.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. , 2009, Tuberculosis.

[25]  V. Buchta,et al.  Synthesis and antimycobacterial evaluation of substituted pyrazinecarboxamides. , 2008, European journal of medicinal chemistry.

[26]  W. Jacobs,et al.  Inhibition of Isolated Mycobacterium tuberculosis Fatty Acid Synthase I by Pyrazinamide Analogs , 2007, Antimicrobial Agents and Chemotherapy.

[27]  C. Vilchèze,et al.  Pyrazinoic Acid and Its n-Propyl Ester Inhibit Fatty Acid Synthase Type I in Replicating Tubercle Bacilli , 2006, Antimicrobial Agents and Chemotherapy.

[28]  Ying Zhang,et al.  Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. , 2006, The Journal of antimicrobial chemotherapy.

[29]  V. Buchta,et al.  Substituted pyrazinecarboxamides: synthesis and biological evaluation. , 2006, Molecules.

[30]  R. Pratt,et al.  Synthesis and reactivity with beta-lactamases of a monobactam bearing a retro-amide side chain. , 2006, Bioorganic & medicinal chemistry letters.

[31]  J. Kuneš,et al.  Heterocyclic isosters of antimycobacterial salicylanilides. , 2005, Farmaco.

[32]  R. Pratt,et al.  Benzopyranones with retro-amide side chains as (inhibitory) β-lactamase substrates , 2004 .

[33]  R. Pratt,et al.  Benzopyranones with retro-amide side chains as (inhibitory) beta-lactamase substrates. , 2004, Bioorganic & medicinal chemistry letters.

[34]  Ying Zhang,et al.  Susceptibility of Mycobacterium tuberculosis to weak acids. , 2003, The Journal of antimicrobial chemotherapy.

[35]  R. Pratt,et al.  New substrates for β-lactam-recognizing enzymes: Aryl malonamates , 2003 .

[36]  R. Pratt,et al.  New substrates for beta-lactam-recognizing enzymes: aryl malonamates. , 2003, Biochemistry.

[37]  Clifton E. Barry,et al.  Effects of Pyrazinamide on Fatty Acid Synthesis by Whole Mycobacterial Cells and Purified Fatty Acid Synthase I , 2002, Journal of bacteriology.

[38]  M. Doležal,et al.  Substituted Amides of Pyrazine-2-carboxylic acids: Synthesis and Biological Activity. , 2002, Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry.

[39]  William R. Jacobs,et al.  Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis , 2000, Nature Medicine.

[40]  Brett M. Bode,et al.  MacMolPlt: a graphical user interface for GAMESS. , 1998, Journal of molecular graphics & modelling.

[41]  L. Collins,et al.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium , 1997, Antimicrobial agents and chemotherapy.

[42]  R. Ottanà,et al.  Aminopyrazinyl derivatives: synthesis and evaluation of antiinflammatory and related activities. , 1994, Farmaco.

[43]  T. Sambaiah,et al.  Synthesis of 2-Aryl-(1,2,4)triazolo(1,5-a)pyrazines. , 1992 .

[44]  T. Kiyotaki,et al.  [Studies on the synthesis of pyrazinoic acid derivatives. II. Derivatives of 3-aminopyrazinoic acid]. , 1961, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.